In light of the evidence for duvelisib in R/R PTCL-TFH as well as its use for bridging to allograft bone transplantation, what can specialists draw on to guide their use of duvelisib-centric regiments in R/R patients?

Name: In light of the evidence for duvelisib in R/R PTCL-TFH as well as its use for bridging to allograft bone transplantation, what can specialists draw on to guide their use of duvelisib-centric regiments in R/R patients?
Uploaded: 2025-08-19T00:00:00+00:00

CLICK HERE FOR CME CREDIT Back to Symposium

Created by

Presenter

Steven Horwitz, MD

Associate Attending, Department of Medicine Medical Oncologist, Lymphoma Specialist and Cellular TherapistMemorial Sloan Kettering Cancer Center (MSKCC)New York, New York